Abstract
We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Central Nervous System / drug effects
-
Central Nervous System / immunology
-
Central Nervous System / pathology
-
Chemokines / antagonists & inhibitors*
-
Chemokines / immunology
-
Chemotaxis, Leukocyte / drug effects
-
Chemotaxis, Leukocyte / immunology
-
Disease Progression
-
Double-Blind Method
-
Drug Administration Schedule
-
Humans
-
Immunosuppressive Agents / administration & dosage*
-
Immunosuppressive Agents / adverse effects
-
Magnetic Resonance Imaging
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / immunology*
-
Multiple Sclerosis / pathology
-
Phenylurea Compounds / administration & dosage*
-
Phenylurea Compounds / adverse effects
-
Piperidines / administration & dosage*
-
Piperidines / adverse effects
-
Placebos
-
Receptors, CCR1
-
Receptors, Chemokine / antagonists & inhibitors*
-
Receptors, Chemokine / immunology
-
Signal Transduction / drug effects
-
Signal Transduction / immunology
-
Treatment Outcome
Substances
-
CCR1 protein, human
-
Chemokines
-
Immunosuppressive Agents
-
Phenylurea Compounds
-
Piperidines
-
Placebos
-
Receptors, CCR1
-
Receptors, Chemokine
-
BX 471